Compare Oscar Health Inc (OSCR) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs Twist Bioscience Corp — how do they compare? Oscar Health Inc trades at $33.37 (market cap $10.22B), while Twist Bioscience Corp trades at $163.21 (market cap $10.08B). The key difference: Oscar Health Inc and Twist Bioscience Corp are close in size by market cap, and Oscar Health Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oscar Health Inc for 15 Days and Twist Bioscience Corp for 27 Days on average.
| OSCR | TWST | |
|---|---|---|
Market Cap | $10.22B | $10.08B |
Volume | 4,123,394 | 4,229,037 |
Sector | Health | Health |
52-Week High | $33.81 | $205.00 |
52-Week Low | $10.85 | $25.45 |
Typical Hold Time | 15 Days | 27 Days |
Enterprise Value | $6.57B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSCR trades at $33.05, up 0.43% today, with strong technical momentum indicated by bullish moving averages. The company shows impressive growth with Q1 and Q2 2026 EPS beats and projected 2026 revenue of $15.3B. Valuation metrics appear reasonable with P/S of 0.63 and EV/EBITDA of 7.79, while profitability metrics show significant improvement from 2025 losses to projected 2026 net income of $551M.
The outlook remains positive with analyst consensus at $34.00 target and Strong Buy ratings from Zacks. Key opportunities include ACA market share gains and margin expansion, while risks center on rising medical costs and execution of growth targets. The stock faces near-term resistance at $34 with RSI suggesting potential overbought conditions.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
